Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PEG Control Clear all
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 27, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional

RCT: Early Feeding After PEG Placement

NCT04110613
View directory record Official record
Conditions
Critical Illness, Malnutrition, Gastrostomy, Procedural Sequelae, Trauma, Surgery, Mechanical Ventilation
Interventions
noFast: Start tube feeds within 1 hour of procedure
Dietary Supplement
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

DuraSeal Sealant Post Market Study

NCT00704340
View directory record Official record
Conditions
Elective Cranial Procedures With Dural Incision
Interventions
DuraSeal Dural Sealant System, Standard of Care
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Sep 27, 2026, 2:56 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

NCT00412750
View directory record Official record
Conditions
Hepatitis B
Interventions
Telbivudine (LdT), peginterferon alpha-2a
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
San Diego, California • Ventura, California • Bradenton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

NCT00152386
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CDP870)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

NCT02359825
View directory record Official record
Conditions
Peripheral Nerve Injury
Interventions
Polyethylene glycol (PEG)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

NCT02263079
View directory record Official record
Conditions
Pediatric Immuno-Tolerant Chronic Hepatitis B
Interventions
Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy

NCT04197869
View directory record Official record
Conditions
Constipation, Post-Op Complication
Interventions
Polyethylene Glycol Powder
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bay Shore, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 27, 2026, 2:56 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

NCT00756977
View directory record Official record
Conditions
Colon Cancer
Interventions
BLI850, polyethylene glycol 3350 based bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Mobile, Alabama • Jupiter, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Not applicable Interventional

EGD-assisted Bowel Preparation for Colonoscopy

NCT01563744
View directory record Official record
Conditions
Esophagoscopy Techniques, Colonoscopy
Interventions
EGD-assisted administration of colonoscopy prep, Control Group received standard prep by oral administration
Procedure
Lead sponsor
Rockford Gastroenterology Associates
Other
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Rockford, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

NCT00857272
View directory record Official record
Conditions
Colonoscopy
Interventions
PEG electrolyte lavage solution + bisacodyl - reformulation, PEG electrolyte lavage solution + bisacodyl
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Anaheim, California • Orange, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

NCT00708201
View directory record Official record
Conditions
Postoperative Ileus
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Laguna Hills, California • Aurora, Colorado • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy

NCT00611442
View directory record Official record
Conditions
Bowel Preparation for Colonoscopy
Interventions
lubiprostone, placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 27, 2026, 2:56 AM EDT
Terminated Phase 4 Interventional Results available

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

NCT02977286
View directory record Official record
Conditions
Constipation
Interventions
Naloxegol Oral Tablet, Placebo Oral Tablet, Docusate Sodium 100 Mg oral capsule [Colace], Senna 217 Mg Oral Tablet, Polyethylene Glycols, Bisacodyl 10 mg Suppository, Magnesium Citrate Oral Liquid Product, Methylnaltrexone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

The EVICEL® Neurosurgery Phase III Study

NCT02457546
View directory record Official record
Conditions
Cerebrospinal Fluid Leak
Interventions
EVICEL Fibrin Sealant, Hydrogel sealant
Biological · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

NCT04572906
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
NTX-001
Combination Product
Lead sponsor
Neuraptive Therapeutics Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Gainesville, Florida • Orlando, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 27, 2026, 2:56 AM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 27, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2011 · Synced Sep 27, 2026, 2:56 AM EDT